Liu Min-Pei, Guo Xiao-Zhong, Xu Jian-Hua, Wang Di, Li Hong-Yu, Cui Zhong-Min, Zhao Jia-Jun, Ren Li-Nan
Department of Experimental Medicine, Northern Hospital, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China.
World J Gastroenterol. 2005 Dec 28;11(48):7671-5. doi: 10.3748/wjg.v11.i48.7671.
To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb) in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any clinical significance in distinguishing pancreatic cancer from other gastrointestinal diseases.
Six hundred and ninety-five serum specimens obtained from 115 patients with pancreatic cancer, 154 patients with digestive cancer and 95 patients with non-digestive cancer were used and classified in this study. Serum specimens obtained from 140 patients with benign digestive disease and 89 patients with non-benign digestive disease served as controls. Ascites was tapped from 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer and 6 severe necrotic pancreatitis patients. The samples were quantitated by solid-phase radioimmunoassay. The cut-off values (CV) of 41, 80, and 118 U/mL were used.
The average intra- and interassay CV detected by immunoradiometric assay of SC6-Ag was 5.4% and 8.7%, respectively. The sensitivity and specificity were 73.0% and 90.9% respectively. The levels in most malignant and benign cases were within the normal upper limit. Among the 16 pancreatic cancer cases, the concentration of SC6-Ag in ascites was over the normal range in 93.8% patients. There was no significant difference in the concentration of SC6-Ag. Decreased expression of SC6-Ag in sera was significantly related to tumor differentiation. The concentration of SC6-Ag was higher in patients before surgery than after surgery. The specificity of SC6-Ag and CA19-9 was significantly higher than that of ultrasound and computer tomography (CT) in pancreatic cancer patients. Higher positive predictive values were indicated in 92.3% SC6-Ag and 88.5% CA19-9, but lower in 73.8% ultrasound and 76.2% CT.
The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer. The detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery.
检测单克隆抗体（MAb）识别的新抗原SC6（SC6-Ag）在胰腺癌及其他恶性或良性疾病患者中的浓度，了解SC6-Ag在鉴别胰腺癌与其他胃肠道疾病方面是否具有临床意义。
本研究使用并分类了从115例胰腺癌患者、154例消化道癌患者和95例非消化道癌患者中获取的695份血清标本。从140例良性消化系统疾病患者和89例非良性消化系统疾病患者中获取的血清标本作为对照。对16例胰腺癌患者、19例肝癌患者、16例结肠癌患者、10例胃癌患者和6例重症坏死性胰腺炎患者进行腹水穿刺。采用固相放射免疫分析法对样本进行定量分析。使用41、80和118 U/mL的临界值（CV）。
免疫放射分析检测SC6-Ag的批内和批间平均变异系数分别为5.4%和8.7%。敏感性和特异性分别为73.0%和90.9%。大多数恶性和良性病例的水平在正常上限范围内。在16例胰腺癌病例中，93.8%患者腹水中SC6-Ag浓度超过正常范围。SC6-Ag浓度无显著差异。血清中SC6-Ag表达降低与肿瘤分化显著相关。术前患者SC6-Ag浓度高于术后。在胰腺癌患者中，SC6-Ag和CA19-9的特异性显著高于超声和计算机断层扫描（CT）。SC6-Ag的阳性预测值为92.3%，CA19-9为88.5%，但超声为73.8%，CT为76.2%，较低。
SC6-Ag与CA19-9联合检测可提高原发性癌症的诊断率。SC6-Ag检测在胰腺癌手术前后的诊断中具有价值。
